Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice

Life Sciences

Volumn 84, Issue 25-26, 2009, Pages 876-881

  Liu, Xibao ^a   Harada, Norio ^a   Yamane, Shunsuke ^a   Kitajima, Lisa ^b   Uchida, Saeko ^b   Hamasaki, Akihiro ^a   Mukai, Eri ^a,c   Toyoda, Kentaro ^a   Yamada, Chizumi ^a   Yamada, Yuichiro ^a,d   Seino, Yutaka ^a,e   Inagaki, Nobuya ^a,f  

^a KYOTO UNIVERSITY   (Japan)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

^c Japan Association for the Advancement of Medical Equipment   (Japan)

^d AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KANSAI ELECTRIC POWER CO   (Japan)

^f JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Dipeptidyl peptidase IV (DPP IV); DPP IV inhibitor; Gastric inhibitory polypeptide (GIP); Glucagon like peptide 1 (GLP 1); Incretin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; CONTROLLED STUDY; ENZYME INHIBITION; FLUID INTAKE; FOOD INTAKE; GLUCOSE TOLERANCE; INSULIN RELEASE; LIPID DIET; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; BODY COMPOSITION; BODY WEIGHT; DIETARY FATS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GASTRIC INHIBITORY POLYPEPTIDE; GENE EXPRESSION; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; INSULIN; ISLETS OF LANGERHANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RNA, MESSENGER; TIME FACTORS;

MUS;

EID: 67349149064     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.03.022     Document Type: Article

References (29)

1. Ahrén B., Simonsson E., Larsson H., Landin-Olsson M., Torgeirsson H., Jansson P.A., Sandqvist M., Båvenholm P., Efendic S., Eriksson J.W., Dickinson S., and Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25 5 (2002) 869-875
2. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., and Baron A.D. Exenatide-113 Clinical Study Group. Effects of Exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 11 (2004) 2628-2635
3. Conarello S.L., Li Z., Ronan J., Roy R.S., Zhu L., Jiang G., Liu F., Woods J., Zycband E., Moller D.E., Thornberry N.A., and Zhang B.B. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 100 11 (2003) 6825-6830
4. Deacon C.F., Danielsen P., Klarskov L., Olesen M., and Holst J.J. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 50 7 (2001) 1588-1597
5. Flock G., Baggio L.L., Longuet C., and Drucker D.J. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of Vildagliptin in mice. Diabetes 56 12 (2007) 3006-3013
6. Fukushima H., Hiratate A., Takahashi M., Mikami A., Saito-Hori M., Munetomo E., Kitano K., Chonan S., Saito H., Suzuki A., Takaoka Y., and Yamamoto K. Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. Bioorganic & Medicinal Chemistry 16 7 (2008) 4093-4106
7. Green B.D., Liu H.K., McCluskey J.T., Duffy N.A., O'Harte F.P., McClenaghan N.H., and Flatt P.R. Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1. Diabetes, Obesity & Metabolism 7 5 (2005) 563-569
8. Hansotia T., Maida A., Flock G., Yamada Y., Tsukiyama K., Seino Y., and Drucker D.J. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. The Journal of Clinical Investigation 117 1 (2007) 143-152
9. Harada N., Yamada Y., Tsukiyama K., Yamada C., Nakamura Y., Mukai E., Hamasaki A., Liu X., Toyoda K., Seino Y., and Inagaki N. A novel gastric inhibitory polypeptide (GIP) receptor splice variant influences GIP sensitivity of pancreatic {beta}-cells in obese mice. American Journal of Physiology. Endocrinology and Metabolism 294 1 (2008) E61-E68
10. Komatsu R., Matsuyama T., Namba M., Watanabe N., Itoh H., Kono N., and Tarui S. Glucagonostatic and insulinotropic action of glucagon-like peptide-1-(7-36) amide. Diabetes 38 7 (1989) 902-905
11. Lamont B.J., and Drucker D.J. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat-fed mice. Diabetes 57 1 (2008) 190-198
12. Lynn F.C., Pamir N., Ng E.H., McIntosh C.H., Kieffer T.J., and Pederson R.A. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty zucker rats. Diabetes 50 5 (2001) 1004-1011
13. Marguet D., Baggio L., Kobayashi T., Bernard A.M., Pierres M., Nielsen P.F., Ribel U., Watanabe T., Drucker D.J., and Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proceedings of the National Academy of Sciences of the United States of America 97 12 (2000) 6874-6879
14. Miyawaki K., Yamada Y., Ban N., Ihara Y., Tsukiyama K., Zhou H., Fujimoto S., Oku A., Tsuda K., Toyokuni S., Hiai H., Mizunoya W., Fushiki T., Holst J.J., Makino M., Tashita A., Kobara Y., Tsubamoto Y., Jinnouchi T., Jomori T., and Seino Y. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Medicine 8 7 (2002) 738-742
15. Nagakura T., Yasuda N., Yamazaki K., Ikuta H., Yoshikawa S., Asano O., and Tanaka I. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochemical and Biophysical Research Communications 284 2 (2001) 501-506
16. Naitoh R., Miyawaki K., Harada N., Mizunoya W., Toyoda K., Fushiki T., Yamada Y., Seino Y., and Inagaki N. Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice. Biochemical and Biophysical Research Communications 376 1 (2008) 21-25
17. Pospisilik J.A., Stafford S.G., Demuth H.U., Brownsey R., Parkhouse W., Finegood D.T., McIntosh C.H., and Pederson R.A. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) zucker rats. Diabetes 51 4 (2002) 943-950
18. Reimer M.K., Holst J.J., and Ahrén B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. European Journal of Endocrinology/European Federation of Endocrine Societies 146 5 (2002) 717-727
19. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G., Greig N.H., and Egan J.M. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141 6 (2000) 1936-1941
20. Thorens B., Dériaz N., Bosco D., DeVos A., Pipeleers D., Schuit F., Meda P., and Porret A. Protein kinase A-dependent phosphorylation of GLUT2 in pancreatic beta cells. The Journal of Biological Chemistry 271 14 (1996) 8075-8081
21. Toyoda K., Okitsu T., Yamane S., Uonaga T., Liu X., Harada N., Uemoto S., Seino Y., and Inagaki N. GLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosis. Biochemical and Biophysical Research Communications 367 4 (2008) 793-798
22. Tsukiyama K., Yamada Y., Yamada C., Harada N., Kawasaki Y., Ogura M., Bessho K., Li M., Amizuka N., Sato M., Udagawa N., Takahashi N., Tanaka K., Oiso Y., and Seino Y. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Molecular Endocrinology 20 7 (2006) 1644-1651
23. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P., Smith D.M., Ghatei M.A., Herbert J., and Bloom S.R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 6560 (1996) 69-72
24. Wang X., Zhou J., Doyle M.E., and Egan J.M. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 142 5 (2001) 1820-1827
25. Widmann C., Dolci W., and Thorens B. Desensitization and phosphorylation of the glucagon-like peptide-l (GLP-1) receptor by GLP-1 and 4-Phorbol 12-Myristate 13-Acetate. Molecular Endocrinology 10 1 (1996) 62-75
26. Willms B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., and Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. The Journal of Clinical Endocrinology and Metabolism 81 1 (1996) 327-332
27. Winzell M.S., and Ahrén B. Durable islet effects on insulin secretion and protein kinase A expression following exendin-4 treatment of high-fat diet-fed mice. Journal of Molecular Endocrinology 40 2 (2008) 93-100
28. Xu G., Kaneto H., Laybutt D.R., Duvivier-Kali V.F., Trivedi N., Suzuma K., King G.L., Weir G.C., and Bonner-Weir S. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: Possible contribution to impaired incretin effects in diabetes. Diabetes 56 6 (2007) 1551-1558
29. Yasuda N., Nagakura T., Yamazaki K., Inoue T., and Tanaka I. Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life Sciences 71 2 (2002) 227-238